Quality aspects during Prequalification Evaluation of vaccines

> DCVMN meeting Sao Paulo UNICEF, Copenhagen 8- 9 October 2014 Carmen Rodriguez Hernandez World Health Organization, EMP/RHT/PQT rodriguezhernandezc@who.int



WHO PREQUALIFICATION PROGRAMME

Outline

- Differences between vaccines and pharmaceutical
- Quality relationship
- GMP concept
- Quality aspects during PQ evaluation
- Regulatory consideration
- Programmatic considerations
- Site audit



Pharmaceuticals Vs Vaccines

Pharmaceuticals


Produced and controlled using physicochemical methodologies

Vaccines

Quality considerations

- Raw materials
- Manufacturing processes
- Quality control methodologies





WHO PREQUALIFICATION PROGRAMME

Each vaccine is an unique product

Different strains of bacteria or viruses can be used by different manufacturers for the same vaccine

» (eg Measles: Schwartz or Edmonston Zagreb)

One company may make their vaccine in many bottles, and another may make the same vaccine in a single large fermentation tank.

The same virus may be grown in one type of cell by company A and in a different cell by Company B.

The same vaccine from one company may not use the same stabilizers or preservatives as another company.



Quality Relationships

Sampling Specifications Testing

Quality Control

GMP

Personnel Training Responsibility Validation Self inspection



Good Manufacturing Practice (GMP)

World Health Organization defines GMP as:

"that <u>part of quality assurance</u> which ensures that products are <u>consistently</u> produced and controlled to the <u>quality standards</u> appropriate to their <u>intended</u> <u>use</u> and as required by the <u>marketing authorization</u>"




Quality Relationships



Quality Management

Complex release process



Quality aspects during PQ evaluation



Specific aspects considered

- General understanding of production process and quality control methods
- Production consistency at commercial scale (assessed by testing of samples of final product)
- Compliance with GMP
- Compliance with WHO recommendations and UN tender specifications including labels and inserts
- Programmatically suitable presentation
- Clinical data relevant for the target population in the recommended schedules



Chapter 5: Production

5.1 Manufacturing formula

- 5.2 Description and flow chart of Manufacturing & testing
- **5.3 General policy for process validation**
- 5.4 Handling starting material, packaging material, bulk and finished products (Sampling, quarantine, release and storage).

5.5 Handling and procedures for destruction of rejected materials and products.



Chapter 6: Quality Control (1)

6.1 Starting material

- 6.1.1 Raw material
- 6.1.2 Labelling and packaging
- 6.1.3 Qualification of suppliers




Chapter 6: Quality Control (2)

6.2 Intermediate products 6.3 Finished product

Specifications and routine tests

Validations





Chapter 7: Stability data

7.1 Intermediate products

7.2 Finished product : vaccine 7.3 Finished product : diluent & reconstituted product

7.4 Policy for assigning the date of manufacture of each component, final product and diluent



Regulatory considerations

 Need to ensure that adequate regulatory pathway is in place, that product is licensed, continuous regulatory oversight in place

Need to assess quality

- Adequacy of production process
- Adequacy of quality control methods and specifications
- Stability data
- Transferability of testing methods to NCL and independent labs
- Consistency of production
- GMP compliance, adequate Quality Management System in place



Programmatic considerations (1)

- Vaccine used in the country of origin?
- Compatible with the existing EPI schedules?
- Stability profile: understanding of the cold chain requirements/ suitability for use under field conditions
- Stability profile: VVM category required
- Packaging: Volume of cold space required



Programmatic considerations (2)

- Presentation/primary packaging suitable?
- Open vial policy applicable?
- Information on inserts: adequate?, clear, reflects product characteristics? Available in all required languages?

Transport boxes validated for international shipments?



Outcome of the review of PSF

Scenario 1: PSF review does not raise any outstanding issues

Scenario 2: PSF review raises outstanding issues for clarification/additional information (no major)

Scenario 3: PSF review raises major technical and programmatic issues Consistency testing is scheduled

Outstanding issues may be followed up at site audit &/or request for additional information **Consistency testing is scheduled**

Ad Hoc committee is convened Request for additional information to give final recommendation Stopping the PQ



Timing for site audit

File review quality and clinical completed

Satisfactory outcome

Consistency Testing completed SITE AUDIT SCHEDULE



Objectives



Product is produced in accordance to WHO GMP recommended requirements



Product meets the WHO recommended requirements for quality, safety and efficacy (TRS documents)



Product meets the specifications of the UN tenders



Scope of Site Audit

- Personnel- Organization
- Facilities and Equipment (Warehouses, production areas, QC laboratories, animal house, etc)
- Utilities
- Quality systems, Quality Assurance unit
- Production process and in process controls
- Quality control facilities, equipment and methods



Aspects considered: Quality System

Quality assurance unit, roles and responsibilities

Documentation system, documentation and records control

Training program

- Post-marketing surveillance, including investigation of complaints and safety and efficacy reports
- **Vendors qualifications**
- Lot release system
- Investigation of complaints
- Validation master plan







Aspects considered: Quality System

Handling and investigation of deviations CAPA, Recall, returns and destruction procedures Reprocess, Rework and Returned Product Internal and external audits Personnel Annual Product Review Maintenance Program, pest control, environmental contro Site master plan





Production System

Media preparation area and process Bulk production area and process Storage areas In process controls Change over procedures Environmental monitoring Gowning procedures Formulation and filling





Production System

Inspection Labeling, Packaging and Shipping procedures Change over procedures Change Control Handling of Deviations Procedures, Process and systems validation Sanitation and hygiene: Cleaning validation Batch manufacturing records





Quality Control System

Testing methods in place and their validation Tests for intermediates and final products SOPs

Sampling procedures

Stability Program

Documentation control

Quality control facilities and equipment, including animal house

Test results and trends- Handling of out of specifications



Facilities and Equipment

Quality of construction, flow of: personnel, product, materials, wastage and process

- Utilities (HVAC, Pressure differentials, water systems, clean steam, compressed air)
- Clean rooms, Classification
- Equipment qualification: DQ, IQ, OQ and PQ
- **Equipment calibration and verification**
- Validation of computerized systems



Key elements for success

- High commitment from management to Quality Products and to implementation of Quality Systems
- Full independence between production, Quality Control and Quality Assurance.
- Sound and controlled documentation system, detailed procedures (SOPs), detailed records (BPR)
- Well trained staff recording all data in BPR immediately, second check by supervisor. Staff trained to opening deviation reports and related investigation
- Presence of QA in production, major role in review of records, investigation of deviations, internal audits and CAPA system
- QC and QA dimensioned and equipped to match production capacity in volume and diversity of products



Main reasons for failure

Lack of commitment from management to Quality Roles and responsibilities at different levels not well defined Wish to rush products into the market without enough process robustness and experience Weak QA, weak quality systems in place not matching production needs Show driven by production head or directors Lack of transparency and honesty with auditors Lack of capacity to identify, investigate and correct gaps in their systems



Site Audit Outcome

